NCIt definition : An antibody-drug conjugate (ADC) composed of a human immunoglobulin (Ig) G1 monoclonal
antibody directed against the T-cell checkpoint ligand B7-H4 (V-set domain-containing
T-cell activation inhibitor 1; VTCN1; B7x; B7S1) linked to the microtubule-disrupting
cytotoxic agent monomethyl auristatin E (MMAE), via a protease-cleavable peptide linker,
with potential antineoplastic activity. Upon administration of anti-B7-H4 ADC SGN-B7H4V,
the anti-B7-H4 monoclonal antibody moiety targets and binds to B7-H4 expressed on
tumor cells. Upon binding, internalization and linker cleavage, MMAE binds to tubulin
and inhibits tubulin polymerization, which results in G2/M phase arrest and apoptosis
specifically in B7-H4-expressing tumor cells. B7-H4, a member of the B7 family of
immune modulators, is upregulated in a variety of tumor cell types and tumor-associated
macrophages (TAMs). It negatively regulates T-cell immune responses. In addition,
SGN-B7H4V may also kill B7-H4-expressing tumor cells through antibody-dependent cellular
cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP).;
UNII : VG5Y3A9DFS;
CAS number : 2924808-30-8;
Molecule name : SGN-B7H4V; SGN B7H4V; PF 08046048; PF-08046048;
CISMeF manual mappings